Abstract
Intratumoral heterogeneity in lung cancer is essential for evasion of immune surveillance by tumor cells and establishment of immunosuppression. Gathering data reveal that circular RNAs (circRNAs), play a role in the pathogenesis and progression of lung cancer. Particularly Kras-driven circRNA signaling triggers infiltration of myeloid-associated tumor macrophages in lung tumor microenvironment thus establishing immune deregulation, and immunosuppression but the exact pathogenic mechanism is still unknown. In this study, we investigate the role of oncogenic Kras signaling in circRNA-related immunosuppression and its involvement in tumoral chemoresistance. The expression pattern of circRNAs HIPK3 and PTK2 was determined using quantitative polymerase chain reaction (qPCR) in lung cancer patient samples and cell lines. Apoptosis was analyzed by Annexin V/PI staining and FACS detection. M2 macrophage polarization and MDSC subset analysis (Gr1−/CD11b−, Gr1−/CD11b+) were determined by flow cytometry. Tumor growth and metastatic potential were determined in vivo in C57BL/6 mice. Findings reveal intra-epithelial CD163+/CD206+ M2 macrophages to drive Kras immunosuppressive chemoresistance through myeloid differentiation. In particular, monocytic MDSC subsets Gr1−/CD11b−, Gr1−/CD11b+ triggered an M2-dependent immune response, creating an immunosuppressive tumor-promoting network via circHIPK3/PTK2 enrichment. Specifically, upregulation of exosomal cicHIPK3/PTK2 expression prompted Kras-driven intratumoral heterogeneity and guided lymph node metastasis in C57BL/6 mice. Consequent co-inhibition of circPTK2/M2 macrophage signaling suppressed lung tumor growth along with metastatic potential and prolonged survival in vivo. Taken together, these results demonstrate the key role of myeloid-associated macrophages in sustaining lung immunosuppressive neoplasia through circRNA regulation and represent a potential therapeutic target for clinical intervention in metastatic lung cancer.
Similar content being viewed by others
Introduction
Lung cancer is the primary cause of cancer-related deaths worldwide and is clinically characterized by chemoresistance, poor prognosis and limited therapeutic interventions1,2,3. Recent data indicate that tumor macrophages or tumor-associated macrophages (TAMs), which constitute the majority of immune cells in tumor microenvironment (TME) are linked with poor clinical prognosis and acquired chemoresistance4,5. A plethora of studies reveal, TAMs to crosstalk with both stromal and tumor cells. In the TME, supporting the establishment of an immunosuppressive network that favors tumor progression and metastasis6,7. However, the exact mechanism of this interaction remains largely unidentified. Growing evidence has indicated that TAMs activity and performance is vastly regulated by myeloid cells, especially myeloid-derived suppressor cells (MDSCs) which are accountable for the intratumoral heterogeneity in lung cancer8,9. Furthermore, this intratumoral heterogeneity is also triggered by mutant Kras signaling which too supports tumor-dependent immunosuppression10,11.
Circular RNAs (circRNAs) are a class of small noncoding RNAs which have no 5′–3′ polarity and contain no polyA tail12,13. CircRNAs are able to regulate macrophage activity and can function as endogenous miRNA sponges or as RNA-binding protein (RBP) agents and control gene expression14,15. Many circRNA member have been found to be dysregulated in various types of tumors, including breast lung and gastric cancer13,16,17.
In the present study we characterize for the first time the role of circHIPK3/PTK2 in tumor macrophages-related immunosuppression. Our findings show intra-epithelial CD163+/CD206+ M2 macrophages to trigger Kras-dependent immunosuppressive chemoresistance through MDSCs differentiation. Specifically, monocytic MDSC subsets Gr1−/CD11b−, Gr1−/CD11b+ elicited an M2-dependent immune response, creating an immunosuppressive tumor-promoting network via circ HIPK3/PTK2 up regulation. Furthermore, amplification of exosomal circHIPK3/PTK2 expression prompted Kras-driven intratumoral heterogeneity and guided lymph node metastasis in C57BL/6 mice. Overall, these findings reveal a novel crosstalk mechanism between circRNAs and tumor macrophages that promotes lung immunosuppressive metastasis and might be a potential therapeutic target for combating lung cancer metastasis.
Materials and methods
Lung cancer tissue samples
Ninety-six NSCLC tissues and paired adjacent non cancerous lung tissues were collected after informed consent from patients in the AHEPA Hospital, Medical School, Aristotle University of Thessaloniki (Thessaloniki, Greece). Tissue samples were collected in the operating room immediately after surgery with non-tumor tissues sent to Pathology for diagnosis by a certified pathologist. Patients received neither chemotherapy nor radiotherapy before tissue collection. The patient study protocol is based on previous studies18.
Cell culture
Human lung adenocarcinoma cells A549 were grown in DMEM, supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 1 mM sodium pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin (Biochrom AG, Berlin, Germany). The epithelial lung cancer H1299 and H1975 cells were grown in RPMI-1640 (Invitrogen, Carlsbad, USA) and were supplemented with 10% heat-inactivated fetal calf serum (FCS). Both cell lines were grown to confluence and maintained in a humidified atmosphere at 37 °C and 5% CO2.
Flow cytometry
Macrophages analysis was performed using single cell suspensions, following incubation with antibodies (APC Mouse anti-Human CD206, PE Mouse anti-Human CD163, APC-Cy7 Mouse anti-Human CD80, FITC Mouse anti-Human HLA-DR from BD Biosciences, USA) for 1 h at 4 °C. Cells then were washed three times with flow buffer (5 mL), then centrifuged, and resuspended in 1 mL of flow buffer for analysis. Cell analysis was performed using a FACSCalibur flow cytometer (BD Biosciences, USA). Flow cytometric analysis was performed using the FlowJo software.
Macrophage polarization
Macrophage polarization was performed according to a previous method19. Briefly, THP-1 cells were differentiated into M0 macrophages following incubation with 320 nmol/L PMA for 18 h. In order to produce M1-polarized macrophages, THP-1 cells were treated with 320 nmol/L PMA for 12 h and then cultured with 100 nmol/L PMA plus 100 ng/mL lipopolysaccharide (LPS) and 20 ng/mL IFN-γ for a further 48 h. To generate M2-polarized macrophages, THP-1 cells were treated with 320 nmol/L PMA for 12 h and then cultured with 100 nmol/L PMA plus 20 ng/mL IL-4 and 20 ng/mL IL-13 for a further 48 h.
Isolation of macrophages from tumor tissues
Freshly isolated patient-derived tumor tissues (biopsies) were cut into pieces and digested in Buffer A containing 0.1 g/L hyaluronidase (Sigma) 1 g/L type 4 collagenase (Worthington), and 0.01 g/L DNase I (Solarbio, China). Cells were then collected and centrifuged at 600 × g for 5 min. The pellets were resuspended with ACK Lysing Buffer and washed with Buffer A before filtration with a 100-μm filter. Cells were then collected for further isolation of macrophages and other immune cells. This method was performed according to a previous protocol described in the literature with slight modifications20.
Quantitative real-time PCR analysis
For analysis of mature circRNA expression, 1 μg of total RNA was converted to cDNA using Prime-Script cDNA Synthesis Kit (Takara, Shiga, Japan). Following reverse transcription, qRT-PCR analysis was performed using the SYBR Premix kit (Takara). GAPDH was used as a normalization control for all of the samples. The following primers were used: 5′-AATCGTGGTGAACCCATAGTG-3′ (forward) and 5′-CTGCAAGCATTAGCATCCCT 5′-(reverse) for circPTK2, and 5′-TATGTTGGTGGATCCTGTTCGGCA-3′(forward) and 5′-TGGTGGGTAGACCAAGACTTGTGA-3′ (reverse) for circHIPK3. Complete list of all primers is included in Supplementary Table S3. The qPCR was performed on an ABI Prism 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) using SYBR Premix Ex Taq II (TaKaRa), and the 2−∆∆Ct method was used to calculate the mRNA expression.
siRNA targeting circPTK2
The siRNA for circPTK2 knockdown was synthesized by GenePharma (Shanghai, China) to target circPTK2. siRNA was used as a negative control. Briefly, A549 cells were transfected with 80–100 pmol of siRNA using Lipofectamine 2000 (Invitrogen). After 72 h, cells were harvested for qRT-PCR analysis of circPTK2 and linear PTK2 mRNA expression.
Quantification of cytokines by enzyme-linked immunosorbent assay (ELISA)
Cytokine concentration was measured for each experimental condition by ELISA, using commercial kits purchased from R&D Systems (Minneapolis, MN, USA), according to the manufacturer’s guidelines. The cytokine kits included IFN-γ (DY285), TNF-α (DY210), IL-6 (DY206), IL-10 (DY217B), IL-12 (DY1240) and IL-1β (DY201). Positive controls were included in the ELISA kit.
Ex vivo tissue culture
Lung tumor samples from consenting Kras (chemoresistant/chemonaive) cancer patients at the AHEPA Hospital Oncology unit were collected, transferred to research lab in cold media, and processed in a sterile tissue culture hood. The culture protocol is modified based on previous studies21,22.
Animals
Six weeks old male C57BL/6 mice were purchased from the Jackson laboratory (Bar Harbor, ME) and were housed under pathogen-free environment with a 12 h light/12 h dark schedule and fed with an autoclaved diet and water ad libitum. The protocol was performed according to a previous study with minor modifications16. To establish orthotopic xenografts in mice, A549 (3 × 106) cells transfected with siRNA-NC/si-circPTK2 and directly implanted into the upper region of the lungs. Three days later, mice were randomly divided into four groups. Three separate groups of mice (n = 8) were injected subcutaneously in lung section with PLX-3397 (2 mg/kg body weight in 0.1 mL PBS, once a day and 5 days per week for 8 weeks). Control mice (n = 8) were treated the same with vehicle (0.1 mL PBS). After 4 weeks treatment, mice were sacrificed; lungs and lymph nodes were removed for bioluminescence imaging and quantification of tumor burden. For imaging, mice were given ip injections of 150 mg/kg d-luciferin (Xenogen) 10 min before imaging. To quantitate tumor burden, bioluminescence signals were calculated from the imaging data using the Living Image software 3.2 (Xenogen) according to manufacturer's protocols.
Statistical analysis
The results are expressed as mean ± SD from at least three separate experiments performed in triplicate. Statistical analysis was performed according to previous methods23. The differences between groups were determined with a two-tailed Student’s t-test or ANOVA using Graph Pad software. The results represent the mean ± SD of at least three independent experiments. Differences were considered statistically significant at p < 0.05. Statistically significant data are indicated by asterisks (*p < 0.05, **p < 0.01).
Ethics approval and consent to participate
The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board and Ethics Committee of the AHEPA Hospital Medical School, Aristotle University of Thessaloniki.
Consent for publication
The consent forms were signed by every participant and will be provided upon request.
Results
Polarization of CD163+ M2 macrophages is associated with mutant Kras status, CD4+ T cell ratio, and recurrence free survival
To evaluate the clinical significance of M2 macrophages in lung tumor development and effector phenotype acquisition, the expression of TAMs markers (CD68, CD163) in tissue sections from chemoresistant Kras patients was assessed. Statistical analysis revealed an increased percentage of CD68+/CD163+ TAMs to be correlated with depleted T cell levels and immune impediment in chemoresistant Kras (MT) patients (Fig. 1A, Supplementary Table S4). In addition, near the tumor invasive front, relative high levels of CD163+ were detected in LN metastatic Kras patients in advanced stage (Stage III–IV) compared to chemonaive-responding to chemotherapy regimen-early stage individuals, indicating a CD163+/M2 macrophage involvement in tumor propagation (Fig. 1B). Next, we investigated the association between CD163 and CD68 expression with T cell ratio from the peripheral blood of included patients. Findings reveal, a positive correlation between the CD4+/CD163+ and CD8+/CD68+ T cell ratio (Fig. 1C,D) which can be attributed to cross talking between macrophage surveillance and T cell signaling in tumor microenvironment. These T cells/M2 associations in lung epithelium play a key role in clinical prognosis and response to immunotherapeutic approaches. To better understand this mechanism, the clinical significance of CD163 expression in patient overall survival (OS) and recurrence free survival (RFS) analysis was investigated. Prognostic analysis showed that, at the invasive border, upregulated levels of CD163 expression were significantly associated with worse RFS (P = 0.0017). Kaplan–Meier surviving curves were employed for the analysis of the prognostic potential of CD163 in LC patients. Data show that low CD163 intensity was closely associated with better patient prognosis (Fig. 1E,F). Overall, these results indicate the crucial role of CD163 + TAMs at invasive front which promote tumor expansion and affect lung cancer patients survival.
Intra-epithelial CD163+/CD206+ M2 macrophages drive Kras immunosuppressive chemoresistance
To better comprehend the Kras-induced M2 macrophage response, the infiltration of macrophage cellular subsets in lung TME was evaluated. Recent reports provide evidence that certain macrophage subsets can regulate fate of myeloid differentiation, whereas others contribute to immunosuppression maintenance in tumor microenvironment24,25. To validate this distribution of macrophages in tumor stroma, we analyzed the expression of macrophage marker CD68 in patient derived tissues. We found higher density of stromal macrophages in Kras (MT) tissues than in para-cancer or wild type Kras samples (Fig. 2A,B). To further characterize the immunological profiles of these distinct patient groups we analyzed the dispersal of macrophage subsets in lung tissues. Importantly, the percentage of M1 macrophages (CD68+/CD86+) was upregulated in patients from the Kras (WT) group compared to low CD163+/CD206+ M2 ratio in Kras (MT) group (Fig. 2C). Furthermore, the levels of M0 (F4/80+) macrophages where increased during late metastatic stages. Next, in order to further characterize the M2 cell subsets present in lung tumors we compared the profile of CD163+/CD206+ cells isolated from chemoresistant patients with lung or lymph node metastasis with wild type (WT) or mutant (MT) Kras status (Fig. 2C,D). Interestingly, increased CD68+/CD163+ expression was closely associated with low T to MDSC immune infiltration in Kras (MT) patients (Fig. 2D,E). Additionally, CD68+/CD163+ expression was significantly higher in intratumoral LN metastatic regions of Kras patients (MT) indicating a M2-related immunosuppressive phenotype (Fig. 2F). Furthermore, the mRNA expression of distinctive M2 markers (Arg1, IRF4) was increased, in metastatic lymph node tissues, whereas the expression of M1 markers (IRF5, TNF-a, iNOS) was restricted in early stage lung cancer samples (Fig. 2G), indicating T cell immunity suppression at a more advanced disease stage.
Monocytic MDSC subsets Gr1−/CD11b−, Gr1−/CD11b+ trigger M2 macrophage enrichment
To further investigate the mechanism by which M2 macrophages establish lung tumoral immunosuppression we examined the granulocytic/monocytic MDSC expression in lung biopsies. Induction and infiltration of mMDSCs and gMDSCs in M1/M2 regions was measured using FACS analysis. Specifically, MDSC infiltration in M2-rich regions was characterized by the presence of Gr−/CD11− and Gr−/CD11b+ monocytic MDSC cells whereas Gr+/CD11b− gMDSC levels were significantly upregulated in M1 tumoral sections indicating a potential link (Fig. 3A). To better understand this myeloid differentiation and the role of immunosuppression-related expansion of heterogeneous MDSC subsets we investigated mMDSCs and gMDSCs infiltration up to five weeks post A549 tumor implantation. Pulmonary mMDSC infiltration was reduced compared to gMDSC infiltration in primary tumor. In addition, lymphatic gMDSC infiltration was increased 34% by week 3 preceding the metastatic lung lesions detection (Fig. 3B). Furthermore, a positive correlation (R = 0.46, p < 0.001) between the M2/MDSC ratio and M2 cell levels was observed which can be attributed to MDSC differentiation towards a M2 phenotype in lung tumor microenvironment (Fig. 3C). Likewise, M2 macrophages enrichment was characterized by the presence of Ly6G/Ly6C positive cells and their expression was restricted to the invasive edge of M2 rich tumor regions (Fig. 3D,E). However, in M1 rich lesions Ly6G/Ly6C expression was decreased significantly (Fig. 3E,F) followed by co-localization of Ki67 positive tumor cells with MDSCs.
Enhanced circHIPK3/PTK2 expression prompts Kras-driven intratumoral heterogeneity
Recent studies report the dysregulation of circular RNAs (circRNAs) to trigger M2 polarization and prompt macrophage-related chemoresistance26,27. To access this, we investigated the levels of two distinctive circRNAs, circHIPK3 and circPTK2, which play an essential role in lung cancer progression and development28,29. To do so, we performed expression profiles analysis of circHIPK3, circPTK2 in 52 paired samples of NSCLC/Kras and adjacent non tumorous tissues by qRT-PCR. Results reveal that circPTK2 was significantly upregulated in 90.4% (47/52) of the NSCLC tissues examined compared to the levels of circHIPK3 (73.1%, 37/52) from matched adjacent non tumor tissues (Fig. 4A,B). To evaluate the clinical significance of these dysregulated circRNAs in Kras oncogenic signaling, we compared their expression in primary and metastatic Kras (MT) tumor samples. Interestingly, circHIPK3 is expressed in both Kras groups, whereas circPTK2 is highly present in metastatic LN tissues (Fig. 4C). Since circRNAs affect M2 polarization we investigated their role in macrophage differentiation. Intriguingly, we found that circPTK2 is mainly expressed at the tumor invasive front (M1-rich region) and stroma (M2-rich region), while circHIPK3 expression is mainly M2-related and is located into the tumor nest and the invasive periphery of tumor (Fig. 4D). To better estimate the macrophage-dependant circRNA crosstalk, we estimated the three subpopulations of macrophages M0, M1, and M2 using FACS analysis in NSCLC patients. Result analysis of the macrophage characterization showed that pro-tumoral M2 macrophages were more enriched in circPTK2 rather than those with circHIPK3 (58% vs. 32%) (Fig. 4D,E). On the contrary M1 and M0 macrophages co-expressed augmented levels of circHIPK3 (M1: 53% vs. 16%, M0: 11% vs. 5%) whereas, circPTK2 was traced on transient M0/M1 phenotype macrophages (17% vs. 6%) (Fig. 4D,E). Given that infiltrating tumor macrophages (mainly M2 subtype) are largely responsible for tumor progression and metastasis, we assessed circHIPK3/circPTK2 enrichment in macrophage subpopulations from lung, lymph nodes and blood respectively. To our surprise, circHIPK3 was co-expressed mutually in M1/M2 macrophages mainly in lungs and blood indicating its involvement in macrophage-related tumorigenesis (Fig. 4F,G). On the contrary, circPTK2 enrichment in mainly M2-dependent and is located both in primary (lungs) and metastatic (lymph nodes, blood) regions.
Co-inhibition of circPTK2 and M2 macrophages reduces tumor volume and metastatic foci development
To comprehend the tumorigenic role of circPTK2-dependent M2 polarization in lung cancer, we used a tumor mouse model. To do so, we employed specifically designed siRNA targeting circPTK2 along with the M2 macrophage inhibitor PLX-3397. Initially, A549 cells were stably infected with si-circPTK2 or si-NC, which were then injected subcutaneously into C57BL/6 mice. Three weeks post injection, the tumors were removed, weighted and photographed. Analysis of tumor formation revealed a substantial reduction in lung tumor volume of si-circPTK2 -treated mice compared to PBS-treated mice (Fig. 5A). In addition, co-treatment with si-circPTK2/PLX-3397, considerable inhibited tumor growth in comparison with single group treatments (siPTK2 vs. PLX-3397) or control group (PBS) (Fig. 5B). Furthermore, tumors derived from circPTK2/PLX-3397 knockdown clones developed at significantly slower rates than control tumors. Next, we investigated the effect of circPTK2 inhibition on secondary metastasis by using an vivo metastasis assay. Interestingly, we observed a decreased number of lymph node metastatic foci in circPTK2/PLX-3397 group compared with PLX-3397-treated mice (Fig. 5C,D). In order to understand this observed tumor suppression efficacy, intravenous administration of circPTK2 or PLX-3397 was performed in A549-tumor bearing mice. Relative tumor volume assessment revealed significantly higher rates of tumor reduction for circPTK2/PLX-3397 treatment compared to controls (Fig. 5E,F). This was followed by, tumor volume shrinkage and depleted Ki-67 antigen expression in NCs-treated groups. Mice injected with siPTK2 alone had a significantly shorter median overall survival (OS) after tumor implantation (35 days) than mice injected with the siPTK2/PLX-3397 (median OS, 56 days) (Fig. 5G). Thus, these results confirm that PTK2/M2 signaling pathway inhibition restrains lung tumor growth followed by a decrease in metastatic potential which extends survival in vivo.
Exosomal expression of circPTK2 triggers an immunosuppressive metastatic circuit
Latest studies portray circRNA expression to be vastly regulated by exosomes present in lung tumor microenvironment that establish an immunosuppressive niche30,31,32. To verify this, we investigated the differential expression of circHIPK3, circPTK2 in patient-derived serum exosomes. Exosomes were collected from blood of 72 NSCLC patients and 76 healthy donors. Findings show exosomal circPTK2 to be highly expressed in lung cancer patients in comparison with circHIPK3 levels and healthy individuals (Fig. 6A). Furthermore, increased exosomal serum circPTK2/circHIPK3 expression was found in metastatic (Stage III–IV) NSCLC patients compared with the non metastatic (Stage I–II) group indicating an association of exosomal circPTK2/circHIPK3 with lymph node metastasis (Fig. 6B). To better comprehend the circPTK2/circHIPK3 metastatic potential we employed AUC and ROC curves to evaluate the specificity and sensitivity of these circRNAs. Data analysis reveal that in metastatic tissues, the AUC values were 0.640 and 0.787 for circPTK2 and circHIPK3 respectively (Fig. 6C,D). Furthermore, increased exosomal circPTK2 expression was observed in Kras (MT) patients rather than the Kras (MT) group (Fig. 6E). These findings indicate the high clinical sensitivity and specificity of exosomal circPTK2/circHIPK3 which can be used as blood detection index for diagnosis of advanced metastatic cancer in NSCLC patients. To further validate the role of circPTK2 signaling cascade in metastatic potential in tumor stroma were treated metastatic H1299 and H1975 lung cells with si-circPTK2 and Kras/M2 inhibitors and subjected them to invasion or migration analysis respectively (Fig. 6F,G). Co-treatment with siPTK2/PLX-3397 inhibitor significantly reduced the percentage of migrated cells compared with single siPTK2 or PLX-3397 treatments (Fig. 6H). Conversely, cells transfected with siKras/PLX-3397 inhibitors displayed an inferior reduction in migration rates in comparison with siKras inhibitor group or single treatments. Furthermore, cell invasiveness was drastically confined in the siKras/PLX-3397 group (Fig. 6I), whereas co-treatment with siPTK2/PLX-3397 inhibitor reduced the percentage of invaded cells in a lower rate.
Discussion
Gathering data reveal the crucial role of circRNA signaling in tumor progression and development33,34. In our study we describe for the first time the molecular mechanism of interaction between CD163+ M2 macrophages and circHIPK3/PTK2 axis which promotes lung intratumoral immunosuppression (Fig. 7). Our findings provide a biochemical explanation for the clinical association between increased circHIPK3/PTK2 expression and metastatic progression in NSCLC. Recently, circPTK2 was also associated with tumor growth and metastasis in colorectal cancer (CRC) and promoted EMT of CRC cells in vitro and in vivo by binding to vimentin protein on sites Ser38, Ser55 and Ser8235. Furthermore, circPTK2 is also differentially expressed in bladder carcinoma and promotes the proliferation and migration of bladder tumor cells29. In a similar manner, circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer cells36. CircHIPK3 was also found to promote oxaliplatin-resistance in colorectal cancer through autophagy by activating the downstream Bcl-2/beclin1 signaling pathway37. Immature myeloid cells (IMC) in tumor microenvironment can also establish chemoresistance via inflammatory cytokine production and inhibition of lymphocyte homing8,9. In our study, we found monocytic MDSC subsets Gr1−/CD11b−, Gr1−/CD11b+ to be associated with Kras-related chemoresistance via M2 macrophage enrichment. Likewise, exosomes produced by mesenchymal stem cells, drive differentiation of myeloid cells into immunosuppressive M2-polarized macrophages with enhanced l-Arginase activity and IL-10 secretion in breast cancer38,39. In addition, AMPKα1 regulates the immunosuppressive activity and differentiation of tumor-MDSC by regulating the differentiation of monocytic-MDSC (mMDSC) to macrophages, suggesting AMPK inhibition as a potential therapeutic strategy to restore protective myelopoiesis in cancer40. Immunosuppression can also be established through exosomes secreted by immune or tumor cells inside the tumor stroma41,42. Our findings reveal an association of exosomal circPTK2/circHIPK3 expression with lymph node metastatic immunosuppression. Equally, circRNA-002178 can act as a ceRNA to promote PDL1/PD1 expression via sponging miR-34 in cancer cells to induce T-cell exhaustion in lung adenocarcinoma43. Human mutant p53 cancer cells can also reprogram macrophages to TAMs via miR-1246-enriched exosomes. These p53-reprogrammed TAMs favor anti-inflammatory immunosuppression with increased activity of TGF-β44. In summary, we identify a critical role for circPTK2/circHIPK3 in monocytic MDSC differentiation into CD163+ M2 macrophages.
Conclusions
Taken together, this study demonstrates the key role of circRNAs circPTK2/circHIPK3 in Kras-related lung cancer progression through infiltration of CD163+/CD206+ M2 macrophages and monocytic MDSC subset (Gr1−/CD11b−, Gr1−/CD11b+) recruitment. These findings reveal a novel crosstalk mechanism between circRNAs and tumor macrophages that promote Kras-driven lung immunosuppressive metastasis and can serve as a potential therapeutic target for NSCLC.
Data availability
All data generated or analyzed during this study are available from the corresponding author upon reasonable request.
Abbreviations
- TAMs:
-
Tumor-associated macrophages
- TME:
-
Tumor microenvironment
- MDSCs:
-
Myeloid derived suppressor cells
- circRNA:
-
Circular RNA
- RFS:
-
Recurrence free survival
- FOXP3:
-
Forkhead box P3
- IMC:
-
Immature myeloid cells
- IRF4:
-
Interferon regulatory factor 4
- LAG-3:
-
Lymphocyte-activation gene 3
- AMPK:
-
5′ Adenosine monophosphate-activated protein kinase
- GATA-3:
-
GATA binding protein 3
References
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
Hirsch, F. R. et al. Lung cancer: Current therapies and new targeted treatments. Lancet 389, 299–311 (2017).
Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553(7689), 446–454 (2018).
Lankadasari, M. B., Mukhopadhyay, P., Mohammed, S. & Harikumar, K. B. TAMing pancreatic cancer: Combat with a double edged sword. Mol. Cancer. 18(1), 48 (2019).
Cassetta, L. & Pollard, J. W. Targeting macrophages: Therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17(12), 887–904 (2018).
Henze, A. T. & Mazzone, M. The impact of hypoxia on tumor-associated macrophages. J. Clin. Investig. 126(10), 3672–3679 (2016).
Rahma, O. E. & Hodi, F. S. The intersection between tumor angiogenesis and immune suppression. Clin. Cancer Res. 25(18), 5449–5457 (2019).
Groth, C. et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer. 120(1), 16–25 (2019).
Hinshaw, D. C. & Shevde, L. A. The tumor microenvironment innately modulates cancer progression. Cancer Res. 79(18), 4557–4566 (2019).
Zhang, Y. et al. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Mol. Cancer. 18(1), 7 (2019).
Cannataro, V. L. et al. Heterogeneity and mutation in KRAS and associated oncogenes: Evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene 37(18), 2444–2455 (2018).
Wang, Y. et al. Circular RNAs in human cancer. Mol. Cancer. 16(1), 25 (2017).
Meng, S. et al. CircRNA: Functions and properties of a novel potential biomarker for cancer. Mol Cancer. 16(1), 94. https://doi.org/10.1186/s12943-017-0663-2 (2017).
Kristensen, L. S., Hansen, T. B., Venø, M. T. & Kjems, J. Circular RNAs in cancer: Opportunities and challenges in the field. Oncogene 37(5), 555–565 (2018).
Tay, Y., Rinn, J. & Pandolfi, P. P. The multilayered complexity of ceRNA crosstalk and competition. Nature 505(7483), 344–352 (2014).
Goodall, G. J. & Wickramasinghe, V. O. RNA in cancer. Nat. Rev. Cancer. https://doi.org/10.1038/s41568-020-00306-0 (2020).
Shang, Q., Yang, Z., Jia, R. & Ge, S. The novel roles of circRNAs in human cancer. Mol. Cancer. 18(1), 6 (2019).
Anestakis, D. et al. Carboplatin chemoresistance is associated with CD11b+/Ly6C+ myeloid release and upregulation of TIGIT and LAG3/CD160 exhausted T cells. Mol. Immunol. 118, 99–109 (2020).
Genin, M., Clement, F., Fattaccioli, A., Raes, M. & Michiels, C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer 15, 577 (2015).
Xiang, W. et al. Miao HDietary fats suppress the peritoneal seeding of colorectal cancer cells through the TLR4/Cxcl10 axis in adipose tissue macrophages. Signal Transduct. Target Ther. 5(1), 239 (2020).
Domvri, K. et al. Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance via immunosuppressive miR-182/miR-217 signaling and p27/CDK6 regulation. Oncotarget 11(29), 2847–2862 (2020).
Domvri, K. et al. Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis. Clin. Immunol. 222, 108620 (2020).
Zarogoulidis, P. et al. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Cell Signal. 27(8), 1576–1588 (2015).
Linde, N. et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat. Commun. 9(1), 21 (2018).
Ugel, S., De Sanctis, F., Mandruzzato, S. & Bronte, V. Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Investig. 125(9), 3365–3376 (2015).
Chen, Y. G., Satpathy, A. T. & Chang, H. Y. Gene regulation in the immune system by long noncoding RNAs. Nat. Immunol. 18(9), 962–972 (2017).
Yang, X. et al. Silica-induced initiation of circular ZC3H4 RNA/ZC3H4 pathway promotes the pulmonary macrophage activation. FASEB J. 32(6), 3264–3277 (2018).
Chen, G., Shi, Y., Liu, M. & Sun, J. circHIPK3 regulates cell proliferation and migration by sponging miR-124 and regulating AQP3 expression in hepatocellular carcinoma. Cell Death Dis. 9(2), 175 (2018).
Xu, Z. Q., Yang, M. G., Liu, H. J. & Su, C. Q. Circular RNA hsa_circ_0003221 (circPTK2) promotes the proliferation and migration of bladder cancer cells. J. Cell Biochem. 119(4), 3317–3325 (2018).
Li, S. et al. exoRBase: A database of circRNA, lncRNA and mRNA in human blood exosomes. Nucleic Acids Res. 46(D1), D106–D112 (2018).
Wang, Y. et al. Exosomal circRNAs: Biogenesis, effect and application in human diseases. Mol. Cancer. 18(1), 116 (2019).
Hu, W. et al. Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology. Mol. Cancer. 19(1), 102 (2020).
Li, X., Yang, L. & Chen, L. L. The biogenesis, functions, and challenges of circular RNAs. Mol. Cell. 71(3), 428–442 (2018).
Zhong, Y. et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol. Cancer. 17(1), 79 (2018).
Yang, H. et al. CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer. Mol. Cancer. 19(1), 13 (2020).
Chen, X. et al. Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKalpha signaling in STK11 mutant lung cancer. Autophagy 16(4), 659–671 (2020).
Zhang, Y. et al. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637. EBioMedicine 48, 277–288 (2019).
Biswas, S. et al. Exosomes produced by mesenchymal stem cells drive differentiation of myeloid cells into immunosuppressive M2-polarized macrophages in breast cancer. J. Immunol. 203(12), 3447–3460 (2019).
Park, J. E. et al. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene 38(26), 5158–5173 (2019).
Trillo-Tinoco, J. et al. AMPK alpha-1 intrinsically regulates the function and differentiation of tumor myeloid-derived suppressor cells. Cancer Res. 79(19), 5034–5047 (2019).
Whiteside, T. L. Exosomes and tumor-mediated immune suppression. J. Clin. Investig. 126(4), 1216–1223 (2016).
Robbins, P. D. & Morelli, A. E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14(3), 195–208 (2014).
Wang, J. et al. circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma. Cell Death Dis. 11(1), 32 (2020).
Cooks, T. et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9(1), 771 (2018).
Acknowledgements
The author would like to thank Professor Konstantinos Zarogoulidis for reading the manuscript and providing useful comments and advice.
Funding
This research is co-financed by Greece and the European Union (European Social Fund-ESF) through the Operational Programme “Human Resources Development, Education and Lifelong Learning” in the context of the project “Reinforcement of Postdoctoral Researchers—2nd Cycle” (MIS-5033021), implemented by the State Scholarships Foundation (ΙΚΥ).
Author information
Authors and Affiliations
Contributions
D.A., T.K., S.P., conceived and planned the experiments. D.A., S.P., C.B., and P.Z., carried out the experiments. S.P., C.B., and K.P., acquired and analyze data, and managed patients. P.Z., S.P., L.F., and D.M., contributed to sample preparation. C.C., K.D., D.T., and K.P., contributed to the interpretation of the results. H.H., and W.H.-S., took the lead in writing the manuscript. All authors provided critical feedback and helped shape the research, analysis and manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Katopodi, T., Petanidis, S., Domvri, K. et al. Kras-driven intratumoral heterogeneity triggers infiltration of M2 polarized macrophages via the circHIPK3/PTK2 immunosuppressive circuit. Sci Rep 11, 15455 (2021). https://doi.org/10.1038/s41598-021-94671-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-021-94671-x
This article is cited by
-
Mutual regulation of PD-L1 immunosuppression between tumor-associated macrophages and tumor cells: a critical role for exosomes
Cell Communication and Signaling (2024)
-
Regulation of the tumor immune microenvironment by cancer-derived circular RNAs
Cell Death & Disease (2023)
-
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Nature Reviews Clinical Oncology (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.